Skip Navigation

Adalvo successfully launches Enzalutamide in LATAM

29 November 2022

Adalvo is pleased to announce the successful launch of Enzalutamide Soft Gel Capsules in LATAM, fulfilling our commitment to our partners, and strengthening our presence in select LATAM countries.

Our product is Enzalutamide Soft Gel Capsule 40mg that has been developed based on the reference brand Xtandi (Astellas). This Adalvo product has been developed by one of our sister Companies, having a state-of-the-art oncology dedicated facility.

Enzalutamide is indicated in the treatment of metastatic hormone-sensitive prostate cancer. The product sold at around $2.1bn globally in 2021, according to IQVIA, with stable sales over the recent years.

We are proud to add that the film-coated tablet version is also part of our portfolio, so Adalvo will soon be able to cover on the full range of Enzalutamide products.

We believe that Adalvo is amongst the first companies to be launching the product.